West Coast Sarcoma Conference 2024: Keynote – Pathways to Improving Outcomes in Sarcomas – What Sequence will Bring us all Together? Dr. Brian Van Tine

Icon Chair Speaker

Co-chairs

Dr. Shantanu Banerji
Dr. Caroline Holloway
Dr. Lee Cranmer
Dr. Christine Simmons

Icon Chair Speaker

Speaker

Dr. Brian Van Tine

Studies/trials discussed:

  • Meta Analysis: Adjuvant Chemotherapy for locally resectable STS
  • Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
  • A review of trabectedin (ET-743): a unique mechanism of action
  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
  • Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
  • Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
  • Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.
  • Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
  • A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy
  • PARP inhibitors: Synthetic lethality in the clinic